VenkatP
Physician, Growth & Value Stock Investor
Hinge Health's revenue growth and cash generation strengthen its case as a leading non-tech IPO near all-time highs. The attached portfolio-stock analysis projects 46% revenue growth in 2026 and puts Q2 free cash flow at about $100 million, roughly three times the year-earlier level. It lists further revenue and margin expansion as potential catalysts. x.com x.comÂ
Hinge Health is building a constructive cup-and-handle base near its highs while its fundamentals keep moving the right way. Estimates call for 2028 EPS of $4.30 and revenue of $1.5B, nearly double 2026 levels. x.comÂ
Hinge Health is the best name in healthcare information, the hottest industry of the past quarter. Strong new contracts with health plans have boosted its margins significantly, while good cash flow and conservative leverage add a margin of safety. x.comÂ
Hinge Health is fine because money has been funneling into healthcare and out of tech, and the raised-guidance catalyst is now behind it. The stock bounced off its 9-day EMA. x.comÂ
Hinge Health, Navan, Pattern Group and Medline are young IPO leaders breaking out of their IPO bases with strong institutional accumulation while trading above their IPO VWAP. Today's young IPOs showing that pattern often become tomorrow's market leaders. x.comÂ
